Slc2a3-flox Mouse
Common Name
Slc2a3-flox
제품 ID
S-CKO-18711
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-20527-Slc2a3-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Slc2a3-flox Mouse (카탈로그 번호 S-CKO-18711)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Slc2a3-flox
품종 계통계통 ID
CKOCMP-20527-Slc2a3-B6J-VB
유전자명
제품 ID
S-CKO-18711
유전자 별칭
Glut3, Glut-3
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 6
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000032476
NCBI 전사체 ID
NM_011401
타겟 영역
Exon 2~3
유효 영역 크기
~1.9 kb
유전자 연구 개요
Slc2a3, also known as the gene encoding glucose transporter 3 (GLUT3), facilitates glucose diffusion across plasma membranes. It is crucial for ATP generation in the human brain, fueling essential biochemical processes like axonal transport and neurotransmitter release. Besides the central nervous system, GLUT3 is expressed in non-neural organs such as the heart and white blood cells, being involved in energy metabolism. In cancer cells, its overexpression contributes to the Warburg effect [1].
Placental SLC2A3 deficiency in sheep during the first-half of gestation leads to fetal hypoglycemia, reduced fetal development, and altered metabolic hormone concentrations, suggesting it may be the rate-limiting placental glucose transporter [2]. In gastric cancer, SLC2A3 acts as a tumor promoter, accelerating aerobic glycolysis through a SLC2A3-STAT3-SLC2A3 feedback loop and promoting M2 subtype transition of macrophage infiltration [3]. In a Chinese Yunnan population, SLC2A3 (rs3931701) C > T variant increases the risk of congenital heart disease [4]. In oral squamous cell carcinoma, SLC2A3 promotes tumor progression via the lactic acid-promoted TGF-β signaling pathway [5]. In head and neck squamous cell carcinoma, SLC2A3 is a risk gene, associated with immune and tumor components in the tumor microenvironment, suppressing CD8+ T cells [6]. The SLC2A3 rs12842 polymorphism is inversely associated with the risk of Alzheimer's disease [7]. In head and neck squamous cell carcinoma, SLC2A3 may mediate disease progression via the NF-κB/EMT axis and immune responses [8]. In colorectal cancer, SLC2A3 may play a role in disease progression by regulating EMT and PD-L1 mediated immune responses [9]. MiR-103a can inhibit the proliferation of human colon cancer cells by targeting SLC2A3 [10].
In conclusion, Slc2a3 is essential for glucose transport and energy metabolism in various tissues. Its dysregulation is associated with multiple diseases, including fetal growth-related issues, cancer, and neurodegenerative diseases. Studies on Slc2a3, especially through in vivo models, help to understand its role in disease mechanisms, potentially providing novel therapeutic approaches.
References:
1. Ziegler, Georg C, Almos, Peter, McNeill, Rhiannon V, Jansch, Charline, Lesch, Klaus-Peter. 2020. Cellular effects and clinical implications of SLC2A3 copy number variation. In Journal of cellular physiology, 235, 9021-9036. doi:10.1002/jcp.29753. https://pubmed.ncbi.nlm.nih.gov/32372501/
2. Lynch, Cameron S, Kennedy, Victoria C, Tanner, Amelia R, Rozance, Paul J, Anthony, Russell V. 2022. Impact of Placental SLC2A3 Deficiency during the First-Half of Gestation. In International journal of molecular sciences, 23, . doi:10.3390/ijms232012530. https://pubmed.ncbi.nlm.nih.gov/36293384/
3. Yao, Xingxing, He, Zhanke, Qin, Caolitao, Li, Guoxin, Shi, Jiaolong. 2020. SLC2A3 promotes macrophage infiltration by glycolysis reprogramming in gastric cancer. In Cancer cell international, 20, 503. doi:10.1186/s12935-020-01599-9. https://pubmed.ncbi.nlm.nih.gov/33061855/
4. Ma, Lijing, Xu, Jiaxin, Tang, Qisheng, Liu, Jie, Jiang, Lihong. 2022. SLC2A3 variants in familial and sporadic congenital heart diseases in a Chinese Yunnan population. In Journal of clinical laboratory analysis, 36, e24456. doi:10.1002/jcla.24456. https://pubmed.ncbi.nlm.nih.gov/35466476/
5. Jiang, Wei, Xu, Sheng, Li, Ping. 2024. SLC2A3 promotes tumor progression through lactic acid-promoted TGF-β signaling pathway in oral squamous cell carcinoma. In PloS one, 19, e0301724. doi:10.1371/journal.pone.0301724. https://pubmed.ncbi.nlm.nih.gov/38625978/
6. Jiang, Wei, Xu, Sheng, Zhao, Meiqing, Li, Chao. 2024. SLC2A3 promotes head and neck squamous cancer developing through negatively regulating CD8+ T cell in tumor microenvironment. In Scientific reports, 14, 29458. doi:10.1038/s41598-024-79417-9. https://pubmed.ncbi.nlm.nih.gov/39604419/
7. Arseniou, Stylianos, Siokas, Vasileios, Aloizou, Athina-Maria, Hadjigeorgiou, Georgios M, Dardiotis, Efthimios. 2020. SLC2A3 rs12842 polymorphism and risk for Alzheimer's disease. In Neurological research, 42, 853-861. doi:10.1080/01616412.2020.1786973. https://pubmed.ncbi.nlm.nih.gov/32627711/
8. Chai, Fangyu, Zhang, Jingfang, Fu, Tao, Jiang, Yan, Zhang, Jisheng. . Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma. In Channels (Austin, Tex.), 17, 2208928. doi:10.1080/19336950.2023.2208928. https://pubmed.ncbi.nlm.nih.gov/37134043/
9. Gao, Huabin, Liang, Jiangtao, Duan, Jing, Shi, Huijuan, Han, Anjia. 2021. A Prognosis Marker SLC2A3 Correlates With EMT and Immune Signature in Colorectal Cancer. In Frontiers in oncology, 11, 638099. doi:10.3389/fonc.2021.638099. https://pubmed.ncbi.nlm.nih.gov/34211835/
10. Li, Yan, Lei, Hailong, Zhang, Ming, Zhu, Jianbin, Du, Yongzhe. . The Effect of SLC2A3 Expression on Cisplatin Resistance of Colorectal Cancer Cells. In Iranian journal of public health, 50, 2576-2583. doi:10.18502/ijph.v50i12.7941. https://pubmed.ncbi.nlm.nih.gov/36317019/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
